(Q34695851)

English

Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17907109%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17907109%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

type 2 diabetes

0 references

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17907109%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Ingrid Gause-Nilsson

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17907109%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Anders Persson

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17907109%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

GALLANT 7 Study Group

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17907109%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

0 references

publication date

1 September 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17907109%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Diabetes and Vascular Disease Research

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17907109%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17907109%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17907109%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

194-203

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17907109%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons".

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Medical significance of peroxisome proliferator-activated receptors.

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

HDL: a recipe for longevity

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Peroxisome proliferator-activated receptors in inflammation control

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

The epidemiology of low-grade chronic systemic inflammation and type 2 diabetes

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Leptin and incident type 2 diabetes: risk or protection?

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Leptin is associated with increased risk of myocardial infarction.

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Relationship between serum adiponectin and leptin concentrations and body fat distribution

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Weight changes following the initiation of new anti-hyperglycaemic therapies.

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Thiazolidinediones

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Plasma Leptin Levels Are Associated with Coronary Atherosclerosis in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.040

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34695851&oldid=1990958371"